KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash from Discontinued Operations (2022 - 2024)

Travere Therapeutics posted quarterly Cash from Discontinued Operations of 7089000.0 for Q4 2024, down 16.21% year-on-year from 8460751.32 in Q1 2024, and down 14278.0% on a QoQ basis from 50000.0 in Q3 2024.

Travere Therapeutics (TVTX) has 3 years of Cash from Discontinued Operations data on file, last reported at 7089000.0 in Q4 2024.

  • For the quarter ending Q4 2024, Cash from Discontinued Operations fell 16.21% year-over-year to 7089000.0; the trailing twelve-month figure through Sep 2025 stood at 7089000.0 (down 9.7% YoY), and the FY2024 full-year result was 7451000.0, down 116.44% from the prior year.
  • Cash from Discontinued Operations for Q4 2024 stood at 7089000.0, down from 50000.0 in the prior quarter.
  • Across five years, Cash from Discontinued Operations topped out at 22064000.0 in Q4 2022 and bottomed at 7089000.0 in Q4 2024.
  • The 3-year median for Cash from Discontinued Operations is 50000.0 (2024), against an average of 6661000.0.
  • The widest annual swing landed in 2023, when Cash from Discontinued Operations plunged 127.65%; it then retreated 16.21% in 2024.
  • A 3-year view of Cash from Discontinued Operations shows it stood at 22064000.0 in 2022, then slumped by 127.65% to 6100000.0 in 2023, then fell by 16.21% to 7089000.0 in 2024.
  • The last three Cash from Discontinued Operations figures came in at 7089000.0 (Q4 2024), 50000.0 (Q3 2024), and 309000.0 (Q2 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Travere Therapeutics 4.34 Bn 4.26 Bn 102.38 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 -7.09 Mn
Dec 31, 2024 -7.09 Mn
Sep 30, 2024 50,000.00
Sep 30, 2024 50,000.00
Jun 30, 2024 -309,000.00
Jun 30, 2024 -309,000.00
Mar 31, 2024 -103,000.00
Mar 31, 2024 -103,000.00
Dec 31, 2023 -6.10 Mn
Dec 31, 2023 -6.10 Mn
Sep 30, 2023 15.29 Mn
Sep 30, 2023 15.29 Mn
Jun 30, 2023 18.61 Mn
Jun 30, 2023 18.61 Mn
Mar 31, 2023 17.53 Mn
Mar 31, 2023 17.53 Mn
Dec 31, 2022 22.06 Mn
Dec 31, 2022 22.06 Mn